Strs Ohio Acquires 1,900 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Strs Ohio grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 47.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 1,900 shares during the quarter. Strs Ohio’s holdings in Blueprint Medicines were worth $388,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. FMR LLC raised its stake in shares of Blueprint Medicines by 60.8% during the 2nd quarter. FMR LLC now owns 8,576,079 shares of the biotechnology company’s stock worth $433,178,000 after acquiring an additional 3,242,698 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Blueprint Medicines by 14.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,631,687 shares of the biotechnology company’s stock worth $284,457,000 after acquiring an additional 698,562 shares in the last quarter. BlackRock Inc. raised its stake in shares of Blueprint Medicines by 0.9% during the 1st quarter. BlackRock Inc. now owns 5,383,138 shares of the biotechnology company’s stock worth $343,876,000 after acquiring an additional 46,264 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Blueprint Medicines by 12.4% during the 1st quarter. Wellington Management Group LLP now owns 3,908,944 shares of the biotechnology company’s stock worth $249,703,000 after acquiring an additional 431,619 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Blueprint Medicines by 19.8% during the 2nd quarter. State Street Corp now owns 2,716,542 shares of the biotechnology company’s stock worth $137,213,000 after acquiring an additional 449,648 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BPMC. JMP Securities reduced their price objective on shares of Blueprint Medicines from $152.00 to $114.00 and set a “market outperform” rating for the company in a research note on Friday, November 4th. Wedbush decreased their price target on shares of Blueprint Medicines from $120.00 to $106.00 and set an “outperform” rating for the company in a report on Wednesday, November 2nd. Wells Fargo & Company raised shares of Blueprint Medicines from an “underweight” rating to an “equal weight” rating and set a $41.00 price objective on the stock in a report on Monday, January 2nd. HC Wainwright reduced their target price on Blueprint Medicines from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, November 2nd. Finally, The Goldman Sachs Group lowered their price target on Blueprint Medicines from $143.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, November 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.

Insider Activity

In related news, CEO Kate Haviland acquired 1,100 shares of the firm’s stock in a transaction dated Thursday, November 3rd. The stock was acquired at an average price of $43.98 per share, with a total value of $48,378.00. Following the acquisition, the chief executive officer now directly owns 92,281 shares in the company, valued at approximately $4,058,518.38. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Blueprint Medicines news, CEO Kate Haviland purchased 1,100 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, November 3rd. The stock was bought at an average price of $43.98 per share, with a total value of $48,378.00. Following the acquisition, the chief executive officer now owns 92,281 shares of the company’s stock, valued at approximately $4,058,518.38. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $50.09, for a total value of $1,001,800.00. Following the completion of the transaction, the director now directly owns 183,243 shares of the company’s stock, valued at approximately $9,178,641.87. The disclosure for this sale can be found here. Insiders own 3.42% of the company’s stock.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $46.40 on Friday. The stock has a market cap of $2.78 billion, a PE ratio of -3.83 and a beta of 0.64. The business has a 50-day simple moving average of $45.44 and a 200-day simple moving average of $55.19. The company has a quick ratio of 6.79, a current ratio of 6.99 and a debt-to-equity ratio of 0.19. Blueprint Medicines Co. has a 52-week low of $40.78 and a 52-week high of $85.67.

Blueprint Medicines (NASDAQ:BPMC – Get Rating) last issued its quarterly earnings data on Tuesday, November 1st. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.51) by $0.28. The business had revenue of $65.98 million during the quarter, compared to analysts’ expectations of $43.49 million. Blueprint Medicines had a negative return on equity of 56.45% and a negative net margin of 263.54%. On average, equities analysts expect that Blueprint Medicines Co. will post -9.38 EPS for the current year.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.